DOP Session 10

DOP82-90

  • 17:05-18:05 Digital Oral Presentation Session 10: Clinical Epidemiology
    Room: C1-M0, Hall C, Bella Center
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark
      17:05-17:11 DOP82: Direct and indirect costs of Inflammatory Bowel Disease in the biological era; ten years of follow up in a Danish population-based inception cohort
    B. Lo1, I. Vind1, M. K. Vester-Andersen1, 2, F. Bendtsen1, J. Burisch1
    1Copenhagen University Hospital Hvidovre, The Gastro Unit, Hvidovre, Denmark, 2Zealand University Hospital, Medical Department, Koege, Denmark
      17:11-17:17 DOP83: Association of FUT2 and ABO with Crohn’s Disease in Koreans
    H.-S. Lee1,2, B. M. Kim2, S. Jung2, M. Hong2, K. Kim2, J. W. Moon2, J. Baek2, S. W. Hwang3, S. H. Park3, S.-K. Yang3, K. Song2, B. D. Ye3
    1
    KU Leuven, Department of Human Genetics, Laboratory of Complex Genetics, Leuven, Belgium, 2University of Ulsan College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, South Korea, 3Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, South Korea
      17:17-17:23 DOP84: Nationwide incidence and prevalence of Paediatric Inflammatory Bowel Disease in Scotland 2015-2017 demonstrates the highest paediatric prevalence rate recorded worldwide
    C. Burgess1, 2, P. Henderson1, 2, I. Chalmers3, R. Harris4, R. Hansen4, R. Russell4, D. Wilson1, 2
    1
    University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2Royal Hospital for Sick Children, Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom, 3Royal Aberdeen Children's Hospital, Paediatric Gastroenterology and Nutrition, Aberdeen, United Kingdom, 4Royal Hospital for Children, Paediatric Gastroenterology and Nutrition, Glasgow, United Kingdom
      17:23-17:29 DOP85: Rising depression and antidepressant use amongst Inflammatory Bowel Disease patients
    J. Blackwell1, S. Saxena2, C. Alexakis1, E. Cecil2, A. Bottle2, I. Petersen3, 4, M. Hotopf5, R. Pollok1
    1
    St George's Healthcare NHS Trust, Gastroenterology, London, United Kingdom, 2Imperial College London, School of Public Health, London, United Kingdom, 3University College London, Epidemiology and Health Informatics, London, United Kingdom, 4Aarhus University, Biostatistics, Aarhus, Denmark, 5King's College London, Institute of Psychiatry, London, United Kingdom
      17:29-17:35 DOP86: Risk for development of Inflammatory Bowel Disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis: A review and meta-analysis
    W. Eigner1, J. Burisch2, W. Reinisch1
    1
    Medical University of Vienna, Medicine III, Division Gastroenterology and Hepatology, Vienna, Austria, 2Danish Centre for eHealth & Epidemiology, Department of Gastroenterology, Frederikssund, Denmark
      17:35-17:41 DOP87: Multi-parameter data-sets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)
    G.-R. Jones1,2, M. Lyons2, N. Plevris1, P. Jenkinson1, C. Bisset1, J. Fulforth1, C. S. Chuah1, S. Minnis1, S.-L. Gillespie1, W. Brindle1, C. Burgess3, P. Henderson3, D. Wilson3, C. Lees1
    1
    Western General Hospital, Gastroenterology, Edinburgh, United Kingdom, 2University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 3Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, United Kingdom
      17:41-17:47 DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in Inflammatory Bowel Disease patients: A nationwide Danish cohort study
    S. B. Thomsen1, K. H. Allin2, J. Burisch2, C. B. Jensen2, S. Hansen2, L. L. Gluud1, K. Theede1, M. Kiszka-Kanowitz1, A. M. Nielsen1, T. Jess2
    1
    Copenhagen University Hospital Hvidovre, Gastrounit, Medical Division, Copenhagen, Denmark, 2Bispebjerg and Frederiksberg Hospital, Center for Clinical Research and Prevention, Copenhagen, Denmark
      17:47-17:53 DOP89: Final growth in Paediatric Crohn's Disease is impaired also in the era of biologics: A population based analysis from the epiIIRN administrative cohort
    A. Assa1, S. Cohen2, N. Asayag3, N. Dan4, G. Focht4, O. Ledder4, N. Lederman5, E. Matz6, A. Cahan7, R. Balicer8, B. Feldman8, I. Brufman8, D. Turner4
    1
    Schneider Children's Medical Center of Israel Hospital for Children, Petah Tikva, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 4Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel, 5Meuhedet Health Services, Tel Aviv, Israel, Tel Aviv, Israel, 66 Leumit Health Services, Tel Aviv, Israel, Tel Aviv, Israel, 7Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv, Israel, 8Clalit Research Institute, Chief’s Office, Clalit Health Services, Tel Aviv, Israel, Tel Aviv, Israel
      17:53-17:59 DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD. Results after 20 years of follow-up in the IBSEN study.
    A. Ossum1,2, Ø. Palm3, M. Cvancarova4, B. Moum1, 2, M. L. Høivik1, The IBSEN study group
    1Oslo University Hospital, Ullevaal, Gastroenterology, Oslo, Norway, 2University of Oslo, Faculty of Medicine, Oslo, Norway, 3Oslo University Hospital, Rikshospitalet, Rheumatology, Oslo, Norway, 4OsloMet, Faculty of Public Health, Oslo, Norway

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark